Article Information
History
- July 8, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Allan I. Levey1,2,*,
- Deqiang Qiu1,7,
- Liping Zhao1,5,
- William T. Hu1,2,
- Duc M. Duong4,
- Lenora Higginbotham1,
- Eric B. Dammer4,
- Nicholas T. Seyfried1,4,
- Thomas S. Wingo1,2,6,
- Chadwick M. Hales1,2,
- Malú Gámez Tansey3,
- David Goldstein8,
- Anees Abrol9,
- Vince D. Calhoun9,
- Felicia C. Goldstein1,2,
- Ihab Hajjar1,2,
- Anne M. Fagan10,
- Doug Galasko11,
- Steven D. Edland11,
- John Hanfelt1,5,
- James J. Lah1,2 and
- David Weinshenker1,6,*
- 1Goizueta Alzheimer’s Disease Research CenterEmory University, Atlanta, Georgia, 30322, USA
- 2Department of NeurologyEmory University, Atlanta, Georgia, 30322, USA
- 3Department of Physiology Emory University, Atlanta, Georgia, 30322, USA
- 4Department of Biochemistry Emory University, Atlanta, Georgia, 30322, USA
- 5Department of Biostatistics Emory University, Atlanta, Georgia, 30322, USA
- 6Department of Genetics Emory University, Atlanta, Georgia, 30322, USA
- 7Radiology and Imaging Sciences Emory University, Atlanta, Georgia, 30322, USA
- 8NINDS, NIH, Bethesda, MD, 20892, USA
- 9Tri-institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Georgia Institute of Technology, Emory University, Atlanta, GA, 30303, USA
- 10Department of Neurology and Knight ADRC, Washington University, St. Louis, MO, 630130, USA
- 11Department of Neurosciences and ADRC, UCSD, San Diego, CA, 92093, USA
- ↵*Correspondence to: Allan I. Levey MD, PhD Department of Neurology, Emory University School of Medicine, 12 Executive Park Drive, Atlanta, GA 30322, Email: alevey{at}emory.edu, David Weinshenker, PhD Department of Human Genetics Emory University School of Medicine 615 Michael St., Whitehead 301 Atlanta, GA 30329 Email: dweinsh{at}emory.edu
Posted July 08, 2021.
A Phase II Study Repurposing Atomoxetine for Neuroprotection in Mild Cognitive Impairment
